LIPUM AB

Their core work

LIPUM AB is a Swedish biotech SME based in Umeå developing a novel therapeutic approach to treat chronic inflammatory diseases. Their work centers on identifying and validating a specific biological target — distinct from existing drug mechanisms — that could offer new treatment options for patients where current anti-inflammatory therapies fall short. The company followed the classic EU SME instrument pathway: a feasibility study (SME-1, 2016) to validate their concept, followed by a full-scale innovation project (SME-2, 2018–2020) worth over €2.2 million to advance their candidate toward clinical readiness. They operate as an independent research-driven SME, suggesting they hold proprietary IP around their therapeutic target.

What they specialise in

How they've shifted over time

LIPUM AB's H2020 trajectory is short but purposeful: they entered in 2016 with a small feasibility study to test whether their inflammatory disease target was viable, then returned in 2018 with a substantially larger innovation project to advance the same concept toward development. There is no visible pivot or broadening of scope — both projects carry the same core theme under the NOTID acronym. This consistency suggests a focused, single-asset company in the early-to-mid stages of drug development rather than a diversified research organization.

LIPUM AB appears to be a single-focus drug development company advancing one therapeutic concept through successive funding stages; a future collaboration would likely need to align directly with their inflammatory disease target or provide clinical, regulatory, or manufacturing capabilities they lack in-house.

How they like to work

LIPUM AB has acted as project coordinator in both of its H2020 projects, which is unusual for an SME and signals strong initiative and project leadership capacity. However, the recorded data shows zero consortium partners across both projects, suggesting they have run these projects largely as solo ventures — possibly protecting proprietary IP or operating as a very lean team with minimal subcontracting. Potential partners should expect to engage them as a lead organization with a clear agenda, not as a flexible consortium member.

LIPUM AB has no recorded consortium partners across its two H2020 projects, meaning it has not co-developed relationships with other research institutions or companies through EU funding. Their network within the EU research ecosystem appears minimal based on available data, though they may maintain informal collaborations not captured in CORDIS records.

What sets them apart

LIPUM AB stands out as a rare SME that coordinated — rather than joined — both of its EU projects, pointing to a company that drives its own research agenda rather than supporting others. Their sustained focus on a single novel inflammatory target across a multi-year funding arc suggests they have identified a specific biological mechanism with genuine commercial potential. For a consortium looking for a biotech SME with a defined therapeutic asset in the inflammatory disease space, LIPUM AB offers a focused, IP-protective partner based in Umeå's strong biomedical research environment.

Highlights from their portfolio

• Notid
  At €2,219,689 this SME-2 grant represents a major EU validation of LIPUM's therapeutic concept, placing them among the better-funded SME instrument recipients in the health sector.
• NOTID
  The SME-1 feasibility project (2016) that secured €50,000 and directly enabled the subsequent €2.2M grant — demonstrating a textbook proof-of-concept-to-scale funding progression.